Effects of combination therapy with warfarin and bucolome for anticoagulation in patients with atrial fibrillation

Circulation Journal

Volumn 75, Issue 1, 2011, Pages 201-203

  Obata, Hiroaki ^a   Watanabe, Hiroshi ^a   Ito, Masahiro ^a   Hirono, Satoru ^a   Hanawa, Haruo ^a   Kodama, Makoto ^a   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Anticoagulation therapy; Atrial fbrillation; Warfarin

Indexed keywords

BUCOLOME; URIC ACID; WARFARIN;

ABSENCE OF SIDE EFFECTS; AGED; ANTICOAGULATION; ARTICLE; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BARBITURATES; BLOOD COAGULATION; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 78651248175     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0842     Document Type: Article

References (11)

1. Takahashi H, Kashima T, Kimura S, Murata N, Takaba T, Iwade K, et al. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: Application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. Drug Metab Dispos 1999; 27: 1179-1186.
2. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
3. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
4. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fbrillation. Intern Med 2001; 40: 1183-1188.
5. Matsumoto K, Ishida S, Ueno K, Hashimoto H, Takada M, Tanaka K, et al. The stereoselective effects of bucolome on the phar-macokinetics and pharmacodynamics of racemic warfarin. J Clin Pharmacol 2001; 41: 459-464.
6. Osawa M, Hada N, Matsumoto K, Hasegawa T, Kobayashi D, Morimoto Y, et al. Usefulness of coadministration of bucolome in warfarin therapy: Pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions. Int J Pharm 2005; 293: 43-49.
7. Inoue H, Nozawa T, Hirai T, Goto S, Origasa H, Shimada K, et al. Sex-related differences in the risk factor profle and medications of patients with atrial fbrillation recruited in J-TRACE. Circ J 2010; 74: 650-654.
8. Lally JA, Gnall EM, Seltzer J, Kowey PR. Non-antiarrhythmic drugs in atrial fbrillation: A review of non-antiarrhythmic agents in prevention of atrial fbrillation. J Cardiovasc Electrophysiol 2007; 18: 1222-1228.
9. Strazzullo P, Puig JG. Uric acid and oxidative stress: Relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 2007; 17: 409-414.
10. Hagiwara N. Infammation and atrial fbrillation. Circ J 2010; 74: 246-247.
11. Letsas KP, Korantzopoulos P, Filippatos GS, Mihas CC, Markou V, Gavrielatos G, et al. Uric acid elevation in atrial fbrillation. Hellenic J Cardiol 2010; 51: 209-213.